PD ISO/TS 4425:2023



BSI Standards Publication

Genomics informatics — Data elements and their metadata for describing the microsatellite instability (MSI) information of clinical massive parallel DNA sequencing

National foreword

This Published Document is the UK implementation of ISO/TS 4425:2023.

The UK participation in its preparation was entrusted to Technical Committee IST/35, Health informatics.

A list of organizations represented on this committee can be obtained on request to its committee manager.

Contractual and legal considerations

This publication has been prepared in good faith, however no representation, warranty, assurance or undertaking (express or implied) is or will be made, and no responsibility or liability is or will be accepted by BSI in relation to the adequacy, accuracy, completeness or reasonableness of this publication. All and any such responsibility and liability is expressly disclaimed to the full extent permitted by the law.

This publication is provided as is, and is to be used at the recipient's own risk.

The recipient is advised to consider seeking professional guidance with respect to its use of this publication.

This publication is not intended to constitute a contract. Users are responsible for its correct application.

This publication is not to be regarded as a British Standard.

© The British Standards Institution 2023
Published by BSI Standards Limited 2023

ISBN 978 0 539 17443 4

ICS 35.240.80

Compliance with a Published Document cannot confer immunity from legal obligations.

This Published Document was published under the authority of the Standards Policy and Strategy Committee on 31 May 2023.

Amendments/corrigenda issued since publication

Date	Text affected

PD ISO/TS 4425:2023

TECHNICAL SPECIFICATION

ISO/TS 4425

First edition
2023-04

Genomics informatics — Data elements and their metadata for describing the microsatellite instability (MSI) information of clinical massive parallel DNA sequencing

Informatique génomique — Éléments de données et leurs métadonnées pour décrire les informations relatives à l'instabilité des microsatellites (MSI) du séquençage massif parallèle d'ADN

Reference number
ISO/TS 4425:2023(E)

© ISO 2023



COPYRIGHT PROTECTED DOCUMENT

© ISO 2023

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
CP 401 • Ch. de Blandonnet 8
CH-1214 Vernier, Geneva
Phone: +41 22 749 01 11
Email: copyright@iso.org
Website: www.iso.org

Published in Switzerland

© ISO 2023 – All rights reserved

Contents

Page

Foreword ..... **v**
Introduction ..... **vi**
1 Scope **1**
2 Normative references **1**
3 Terms and definitions **1**
4 Abbreviated terms **5**
5 Microsatellite instability (MSI) **5**
6 Composition of elements for describing MSI status on clinical DNA NGS report **6**
6.1 General 6
6.2 Summary part 7
6.3 Detail part 7
7 Fields and their nomenclature of required data **7**
7.1 General 7
7.2 Clinical sequencing order 8
7.2.1 General 8
7.2.2 Clinical sequencing order code 8
7.2.3 Date and time 8
7.3 Information on subject of care 9
7.3.1 General 9
7.3.2 Subject of care identifier 9
7.3.3 Subject of care name 9
7.3.4 Subject of care birth date 9
7.3.5 Subject of care sex 9
7.3.6 Subject of care ancestry 9
7.3.7 Referring diagnosis 10
7.4 Information on legally authorized person ordering clinical sequencing 10
7.4.1 General 10
7.5 Performing laboratory 10
7.5.1 General 10
7.5.2 Basic information on performing laboratory 10
7.5.3 Information on report generator 10
7.5.4 Information of legally confirmed person on sequencing report 10
7.6 Biospecimen information 10
7.6.1 General 10
7.6.2 Type of specimen 10
7.7 MSI status result information 11
7.7.1 General 11
7.7.2 MSI status 11
7.8 Recommended treatment 11
7.8.1 General 11
7.8.2 Medication 11
7.8.3 Clinical trial information 11
7.8.4 Other recommendations 11
7.8.5 Supporting information 11
8 Fields and their nomenclature of optional data **12**
8.1 General 12
8.2 Reference genome information 12
8.3 MSI information 13
8.3.1 General 13
8.3.2 Criteria of MSI status 13
8.3.3 Genomic position for determining MSI status 13

© ISO 2023 – All rights reserved

8.3.4 Genomic position against markers of alternative method 13
8.3.5 Clinical implication of MSI status 13
8.4 Sequencing information 13
8.4.1 Clinical sequencing date 13
8.4.2 Sequencing type 13
8.4.3 Quality control metrics 14
8.4.4 Sequencing platform information 14
8.4.5 Analysis platform information 14
Annex A (informative) **Example structure of MSI status report** **16**
Bibliography **19**

© ISO 2023 – All rights reserved

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 215, *Health informatics*, Subcommittee SC 1, *Genomics informatics*.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

© ISO 2023 – All rights reserved

Introduction

Massively parallel sequencing is a high-throughput analytical approach to nucleic acid sequencing that allows whole genomes, transcriptomes, and specific nucleic acid targets. These advanced technologies have been used in the clinical field, and clinical sequencing has been applied to realize personalized medicine and precision medicine. ISO/TS 20428[1] has been developed for clinical usage.

In the field of cancer treatment, various treatment strategies were performed differently from traditional anti-cancer chemotherapies. One of those strategies is the control of human immune system that maintains the action to extract cancer cells. Recent outcomes of clinical trials show that this immune therapy is efficient for some patients who have a specific molecular character of their tumor mass, such as PD-L1 or CTLA4 surface protein expression[2]. As a result, these molecular characters are used as biomarkers for selecting patients. In colon cancer, according to several clinical trials, it is reported that the status of MSI (microsatellite instability) is regarded as a biomarker that drugs based on immuno-therapy are more efficient for the patient with MSI-H (high)[3].

The status of MSI can be calculated and reported by small nucleotide deletion on a specific region of human genome reference with NGS sequencing[4]. According to US FDA, four NGS sequencing products were approved for companion diagnostics. Among these products, three NGS sequencing provide MSI status and value on their NGS sequencing report. CLIA-certified labs or equivalent level agencies in countries also are servicing the MSI status from their methods[5]. It is forecasted that more clinical NGS sequencing will be approved to report MSI.

However, there is no standard for describing MSI status, value, and metadata. ISO/TS 20428 focuses on only DNA variations compared with the reference genome. According to some research results, MSI status and the way to describe it are different even if using the same sequencing data. This makes it difficult for clinicians and researchers not only to use MSI status results for clinical decisions but also for secondary analyzing purposes when receiving from more than one sequencing lab. Related metadata should be essential to expand the usage of MSI status results.

In this document, the data elements and their standardized metadata for MSI status in electronic health records will be described. The clinical report for MSI will provide helpful information on bioinformatics analysis to help clinical decisions.

© ISO 2023 – All rights reserved

Genomics informatics — Data elements and their metadata for describing the microsatellite instability (MSI) information of clinical massive parallel DNA sequencing

1 Scope

This document identifies data elements and metadata to represent the information about microsatellite instability (MSI) for reporting the value of the biomarker using clinical massive parallel DNA sequencing.

This document covers information about the MSI test result and related data, such as used resources, data generation condition, and data processing information which are helpful to clinical diagnosis and research.

This document is not intended

— for defining experimental protocols or methods for calculating the value of microsatellite instability (MSI),

— for the other biological species than human resource, or

— for the Sanger sequencing methods.

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 8601 (all parts), *Date and time — Representations for information interchange*

ISO/TS 22220:2011, *Health informatics — Identification of subjects of health care*

ISO/TS 27527:2010, *Health informatics — Provider identification*

3 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

ISO and IEC maintain terminology databases for use in standardization at the following addresses:

— ISO Online browsing platform: available at https://www.iso.org/obp

— IEC Electropedia: available at https://www.electropedia.org/

3.1
biological specimen
biospecimen
specimen
sample of tissue, body fluid, food, or other substance that is collected or acquired to support the assessment, diagnosis, treatment, mitigation or prevention of a disease, disorder or abnormal physical state, or its symptoms

[SOURCE: ISO/TS 20428:2017, 3.34]

© ISO 2023 – All rights reserved